Mometasone Zentiva (Mometasone Furoate Monohydrate)

Mometasone furoate binds to glucocorticoid receptors in nasal mucosal cells, altering gene transcription to suppress the release of inflammatory cytokines, chemokines and other mediators. This reduces swelling, mucus production and the overall inflammatory response in the nasal passages.

The appropriate dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s condition, age and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for mometasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency nasal corticosteroid with a low systemic bioavailability, similar to fluticasone propionate. Compared with some alternatives, it may provide effective symptom control at once‑daily dosing, but the choice of agent depends on individual patient response, tolerability and prescriber preference.

Store the nasal spray at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, excessive heat and direct sunlight. Do not freeze the product, and ensure the cap is tightly closed when not in use.

The spray is intended for intranasal use. The patient should gently blow the nose, insert the tip into one nostril, close the opposite nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, although rare, include adrenal suppression with prolonged high‑dose use, fungal infections of the nasal passages, severe allergic reactions such as anaphylaxis, and structural damage like nasal septum perforation. Patients should report any unusual symptoms promptly to their healthcare provider.

Individuals with known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery without physician approval, or those for whom systemic corticosteroid exposure is contraindicated.